The lncRNAs NNT-AS1 and HOXA-AS3 have been reported to associate with cisplatin resistance, which is the standard adjuvant treatment after chemotherapy for advanced NSCLC [19,20]. Here, NNT is linked to non-small cell lung carcinoma.